Fundraising FoxVenrock Healthcare Capital Partners
Venture capitalNew York · 2 people tracked
Find your way into Venrock Healthcare Capital Partners
Sign up to see every warm intro you have to Venrock Healthcare Capital Partners
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Venrock Healthcare Capital Partners team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Fund manager profile
Venrock Healthcare Capital Partners is a venture fund manager based in New York. SEC filings show 1 venture fund on record, most recently Venrock Healthcare Capital Partners II, L.P. ($200M offering) filed March 2014.
Source: SEC EDGAR Form D filings. Firm website data not yet available.
Team · 2 people
from public directoriesWhat they invest in
from 18 of 18 portfolio companiesBiotech ×16Healthtech ×9Medical Devices ×3AI & Machine Learning ×2Cloud Computing ×1Deep Tech ×1Enterprise Software ×1Fintech ×1
HQs:United States×16
Investments · 18 tracked
founders shown can be your intro pathBy year:2026 · 42025 · 22024 · 32023 · 12022 · 12020 · 12019 · 22018 · 115 dated
Apogee Therapeutics develops engineered antibody therapies to treat inflammatory and immune diseases with reduced injection frequency compared to existing treatments.
BiotechHealthtechMedical Devices
Michael Henderson(Chief Executive Officer and Director)in
Co-investorsAccess BiotechnologyRA CapitalWellington ManagementBlackstone Life SciencesPerceptive Xontogeny VentureRTW Investments L.P.
Damora Therapeutics is a preclinical-stage biotechnology company that discovers and develops therapeutic candidates, including DMR-001, DMR-002, and DMR-003, with the goal of advancing treatments through investigational drug applications and clinical trials.
BiotechCopenhagen, US
Garrett Winslow(Executive Officer)inLori Firmani(Executive Officer)inHans T. Schambye(Executive Officer, Director)Jennifer Jarrett(President, Chief Executive Officer and Director)inBecker Hewes(Chief Medical Officer)Sherwin Sattarzadeh(Chief Operating Officer)
Co-investorsAccess BiotechnologyViking GlobalAndreessen HorowitzBAM ElevateBay City CapitalCommodore Capital+8 more
Maze Therapeutics develops precision medicines for common diseases with high unmet need, using its Compass platform based on human genetics and variant functionalization.
AI & Machine LearningBiotechSouth San Francisco, US
Charles Homcy(Director)Jason Coloma(Chief Executive Officer)in
Co-investorsAndreessen HorowitzARCH Venture PartnersForesite CapitalFrazier Life SciencesGV (Google Ventures)Hercules Capital, Inc.+9 more
Relmada is a clinical-stage biopharmaceutical company developing therapies including NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, and Sepranolone, a candidate targeting compulsive behaviors via GABAA receptor modulation.
BiotechHealthtechNew York, US
Sergio Traversa(Executive Officer, Director)Paul Kelly(Director)Maged Shenouda(Director)inEliseo O. Salinas(President and Chief Scientific Officer)inDouglas Beck(Chief Financial Officer)Charles Ence(Chief Accounting and Compliance Officer)
Co-investorsBioAdvanceBAM ElevateBraidwellCommodore CapitalJanus Henderson InvestorsOrbiMed+2 more
Upstream Bio is a biotechnology company that sponsors clinical trials to develop products under investigation.
BiotechHealthtechWaltham, US
Rand Sutherland(Chief Executive Officer)inAllison Ambrose(General Counsel)inAaron Deykin(Chief Medical Officer & Head of R&D)inMike Gray(Chief Financial Officer and Chief Operating Officer)Adam Houghton(Chief Business Officer)inStacy Price(Chief Technology Officer)in
Co-investorsOrbiMedAccess IndustriesAccess BiotechnologyBain Capital Life SciencesDecheng CapitalHBM Healthcare Investments+5 more
Adverum is a clinical-stage gene therapy company developing Ixo-vec, an investigational single-administration intravitreal treatment for wet age-related macular degeneration and other ocular diseases, based on a proprietary adeno-associated virus (AAV) vector platform.
BiotechDeep TechHealthtechRedwood City, US
Thomas W. Chalberg(Executive Officer, Director)Steven D. Schwartz(Director)Mark S. Blumenkranz(Director)Linda Rubinstein(Executive Officer)Setareh Seyedkazemi(Executive Officer)Kishor Peter Soparkar(Executive Officer)
Co-investorsAvoro Capital AdvisorsFrazier Life Sciences5AM VenturesSamsara BioCapitalVivo Capital
Applied Therapeutics is a biopharmaceutical company developing novel drugs for rare diseases with high unmet medical need.
BiotechHealthtechNew York, US
Shoshana Shendelman(Executive Officer, Director)in
BoardLes Funtleyder(Director)
Co-investorsEvolution VC PartnersAlexandria
A biotechnology company developing new therapies for patients with high unmet medical needs.
Biotech
Co-investorsDolby Family VenturesLifeSci Venture PartnersSofinnova VenturesThe W FundViking GlobalCommodore Capital+6 more
Pharmaceutical company developing medicines and vaccines for patient health and treatment.
BiotechHealthtechSan Diego, US
Jeffrey Stein(Executive Officer, Director)Kevin Judice(Director)inKevin Forrest(Executive Officer)Dirk Thye(Executive Officer)inKen Bartizal(Executive Officer)inPaul Daruwala(Executive Officer)in
Co-investors5AM VenturesAisling CapitalBain Capital Life SciencesFrazier Life SciencesRA CapitalVivo Capital+1 more
BiotechCambridge, US
Chad A. Cowan(Executive Officer, Director)inLeandro Vetcher(Executive Officer)Daniel Vasella(Director)Jim Glasheen(Executive Officer, Director)Neil White(Director)
BoardMartin Murphy(Director)
Co-investorsLifeSci Venture PartnersBain Capital Life SciencesCasdin Capital
BiotechSan Diego, US
Stephen W. Kaldor(Executive Officer, Director, Promoter)Eric Murphy(Executive Officer, Director)
BoardBret Zbar(Director)Carl Gordon(Director)Michael Rome(Director)in
Co-investorsForesite CapitalNextech InvestViking GlobalJanus Henderson InvestorsRA CapitalViking Global Investors
Lycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation.
BiotechHealthtechSouth San Francisco, US
Carolyn Bertozzi(Lycia founder and Professor of Chemistry, Stanford University)inAetna Wun Trombley(President and CEO)inAmy Bachrodt(Chief Financial Officer)inChin Lee(Chief Medical Officer)inSteve Staben(Chief Scientific Officer)inSofia Touami(Chief Business Officer)in
Co-investorsREDMILEVersant VenturesHBM Healthcare InvestmentsHBM PartnersBAM ElevateFranklin Templeton+5 more
Metsera was a clinical-stage biotechnology company developing injectable and oral medicines for obesity and metabolic diseases, including next-generation GLP-1 and amylin-based therapies.
BiotechHealthtechMedical DevicesNew York, US
Clive A. Meanwell(Director)Christopher J. Visioli(Executive Officer)inBrian Hubbard(Executive Officer)inChristopher Whitten Bernard(Executive Officer, Director)Steven Marso(Executive Officer)Clive Meanwell(Founder)
Co-investorsAlpha Wave GlobalARCH Venture PartnersF-Prime CapitalGV (Google Ventures)RA CapitalSoftBank Vision Fund+5 more
Mirador provides digital lending platform software for financial institutions, credit unions, and banks to streamline online loan applications.
Cloud ComputingEnterprise SoftwareFintechSaaS
Co-investorsCore Venture CapitalNycaNyca PartnersARCH Venture PartnersFidelity InvestmentsInvus+3 more
Mirador discovers and develops precision medicines for immune-mediated and immuno-fibrotic diseases using a target-patient matching approach.
AI & Machine LearningHealthtechMedical DevicesSan Diego, US
Mark C. McKenna(Executive Officer, Director)inJoseph Papa(Director)Scott Glenn(Director)Vika Brough(Executive Officer)Timothy K. Andrews(Executive Officer)Mark McKenna(Founder)
Co-investorsAquiline Technology GrowthARCH Venture PartnersOrbiMedSanofi VenturesInvusPoint72
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Concentric AnalgesicsCorvidia TherapeuticsLusaris Therapeutics
Exits · 7
5 IPOs · 2 acquisitions · showing 6Apogee TherapeuticsNASDAQ: APGEDamora TherapeuticsNASDAQ: DMRAMaze TherapeuticsNASDAQ: MAZERelmada TherapeuticsNASDAQ: RLMDUpstream BioNASDAQ: UPBMetseraacq. by Pfizer
Portfolio news
latest coverage across their companiesLycia Therapeutics · finsmes.com · Jun 29, 2026
Mirador Therapeutics · finsmes.com · Jan 13, 2026
Athira · geekwire.com · Dec 18, 2025
Adverum Biotechnologies · biospace.com · Oct 27, 2025
IPO stake values · per SEC filings · 2
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Apogee Therapeutics | 14.8% | $62.00 | Mar 2024 | $108.5M |
| Upstream Bio | 3.5% | $17.00 | Oct 2024 | $30.9M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has Venrock Healthcare Capital Partners made?
- Venrock Healthcare Capital Partners has 18 tracked investments, 7 of which have exited, including 7 dated in the last 24 months.
- Where is Venrock Healthcare Capital Partners located?
- Venrock Healthcare Capital Partners is headquartered in New York, US.